Why It Matters
Trulieve Cannabis Corp. disclosed $300,000 in federal lobbying expenditures for the second quarter of 2026, according to its lobbying disclosure filings submitted on July 6.
The cannabis industry faces ongoing regulatory uncertainty at the federal level, particularly around banking access and the drug's legal status. Trulieve's lobbying activity suggests the company is engaging with Congress on cannabis-related legislation, potentially including banking measures that would address longstanding restrictions on financial services for cannabis businesses.
By the Numbers
Trulieve's second quarter 2026 filing amount of $300,000 represents a significant increase from its first quarter 2025 spending of $37,500, though slightly below its third quarter 2025 expenditures of $275,000. The company reported second quarter 2025 lobbying expenditures of $225,000.
Lauren Niehaus, executive director of government relations at Trulieve, leads the company's federal lobbying efforts. Niehaus previously served in the same capacity for Harvest Health & Recreation Inc., where she lobbied on the SAFE Banking Act of 2021.
The Agenda
A DEA formal rescheduling hearing began on June 29, with proceedings set to conclude no later than July 15. Congressional interest in cannabis banking access has remained consistent. Rep. Brian J. Mast visited Trulieve's West Palm Beach location on August 25, 2025, where he expressed support for greater access to medical marijuana as an alternative to opioids and highlighted its potential benefits for the veteran community.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article